

REVIEW

GATA2 deficiency and MDS/AML: Experimental strategies for disease modelling and future therapeutic prospects

Lili Kotmayer¹  | Damia Romero-Moya²  | Oskar Marin-Bejar²  | Emilia Kozyra^{3,4}  |
 Albert Català^{5,6}  | Anna Bigas^{7,8}  | Marcin W. Wlodarski^{3,9}  | Csaba Bödör¹  |
 Alessandra Giorgetti^{2,10,11} 

¹HCEMM-SE Molecular Oncohematology Research Group, 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary

²Regenerative Medicine Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain

³Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany

⁴Faculty of Biology, University of Freiburg, Freiburg, Germany

⁵Department of Hematology and Oncology, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Barcelona, Spain

⁶Biomedical Network Research Centre on Rare Diseases, Instituto de Salud Carlos III, Madrid, Spain

⁷Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain

⁸Josep Carreras Research Institute (IJC), Badalona, Barcelona, Spain

⁹Department of Hematology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA

¹⁰Fondazione Pisana Per la Scienza ONLUS (FPS), San Giuliano Terme, Italy

¹¹Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Barcelona University, Barcelona, Spain

Correspondence

Alessandra Giorgetti, Bellvitge Institute for Biomedical Research (IDIBELL), Hospital Duran i Reynals-3rd floor Gran Via de l'Hospitalet, 199 08908 Hospitalet de Llobregat, Barcelona, Spain.
 Email: agiorgetti@idibell.cat

Funding information

Bundesministerium für Bildung und Forschung, Grant/Award Number: 2018-123/01KU1904 and BMBF MyPred 01GM1911A; EU's Horizon 2020 Research and Innovation Program, Grant/Award Number: 739593; Fondazione Pisana per la Scienza ONLUS, Grant/Award Number: FPS Grant 2018; Generalitat de Catalunya, Grant/Award Number: CERCA Programme and SLT011/18/00006; Hungarian National Academy of Scientist Education; MSCA No 101029927-scGATA2track, Grant/Award Number: H2020-MSCA-IF-2020; Ministerio de Economía y Competitividad, Grant/Award Number: PID2020-15591RB-100; Nemzeti Kutatási és Technológiai Hivatal, Grant/Award Number: ED-18-1-2019-001, TKP2021-EGA-24, TKP2021-NVA-15 and ÚNKP-21-2-I-SE-21; Vera and Joseph Dresner Foundation; Evans MDS Foundation; American Lebanese Syrian Associated Charities

[Correction added on 06 July 2022, after first online publication: Affiliation 8 was updated in this version.]

Summary

The importance of predisposition to leukaemia in clinical practice is being increasingly recognized. This is emphasized by the establishment of a novel WHO disease category in 2016 called “myeloid neoplasms with germline predisposition”. A major syndrome within this group is GATA2 deficiency, a heterogeneous immunodeficiency syndrome with a very high lifetime risk to develop myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML). GATA2 deficiency has been identified as the most common hereditary cause of MDS in adolescents with monosomy 7. Allogenic haematopoietic stem cell transplantation is the only curative option; however, chances of survival decrease with progression of immunodeficiency and MDS evolution. Penetrance and expressivity within families carrying GATA2 mutations is often variable, suggesting that co-operating extrinsic events are required to trigger the disease. Predictive tools are lacking, and intrafamilial heterogeneity is poorly understood; hence there is a clear unmet medical need. On behalf of the ERAPerMed GATA2 HuMo consortium, in this review we describe the genetic, clinical, and biological aspects of familial GATA2-related MDS, highlighting the importance of developing robust disease preclinical models to improve early detection and clinical decision-making of GATA2 carriers.

KEY WORDS

acute myeloid leukaemia, blood cancer, GATA2 deficiency, myelodysplastic syndromes

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. *British Journal of Haematology* published by British Society for Haematology and John Wiley & Sons Ltd.

INTRODUCTION

Over a decade ago, the first germline pathogenic variants in the *GATA2* gene with a predisposition to myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) were reported by Hahn and colleagues.¹ Since then, a number of germline *GATA2* variants across individual cases and families with associated characteristic haematological and non-haematological phenotypes have been described. Together they define *GATA2* deficiency syndrome, a rare autosomal dominant genetic disease with increased susceptibility to myeloid malignancies and other non-malignant symptoms.² Clinical presentations of *GATA2* deficiency syndrome may range from severe bone marrow failure (BMF), myeloid malignancies, immunodeficiencies and congenital syndromic features to a minority of asymptomatic cases due to partial or incomplete penetrance.^{3,4}

Despite the highly variable manifestations of *GATA2* deficiency, associated phenotypes are now recognized as a single monogenic syndrome, introduced in the revised 2016 WHO classification of haematopoietic tumours as the novel category of "myeloid neoplasms with germline *GATA2* mutations". *GATA2* deficiency syndrome encompasses cellular immunodeficiency disorders, namely MonoMac^{5,6} (monocytopenia and mycobacterial infections) and Emberger syndrome^{7,8} (myelodysplasia and lymphoedema), dendritic cell, monocyte, B- and NK- lymphoid (DCML) deficiency^{9,10} and myeloid malignancies, predominantly familial and primary paediatric MDS and AML.^{1-3,11,12} Germline *GATA2* mutations have also been identified and linked to additional clinical manifestations such as chronic neutropenia,⁵ hypocellular BMF,^{13,14} defects of megakaryopoiesis, B and NK cell deficiency,^{15,16} congenital auditory and neurological disorders (predominantly sensorineural deafness and ADHD)^{17,18} and recurrent miscarriages.^{5,17,19}

Despite the frequent and significant overlap among these clinical features and temporal changes in the clinical presentations over the disease course, no common pathognomonic *GATA2* phenotype has been defined to date. It suggests that different unknown underlying co-operating factors ("stressor events") in specific cellular contexts and processes are required for each *GATA2*-related clinical manifestation, as recently proposed by Homan and colleagues.^{20,21} Amalgamation of an impaired *GATA2* function and the accumulation of stochastic biological or environmental stressors may (substantially) dysregulate a subset of *GATA2*-dependent processes, rattling normal cellular function. This mechanism has been proposed for haematopoietic stem cell (HSC) exhaustion and BMF due to recurrent infections,^{13,22} myeloid malignancies due to acquired somatic alterations, such as *ASXL1* mutations or monosomy 7²³ and presumably lymphoedema due to mechanical or inflammatory stresses of lymphatic vessels and valves during development.²⁴

The ERAPerMed *GATA2* HuMo consortium is an international collaborative network aiming for the precise understanding of *GATA2* deficiency syndrome and subsequent myeloid transformation by combining clinical and genomic

approaches with *in vitro* and *in vivo* models. In this review, we provide an overview of the molecular background of *GATA2* deficiency with an insight into clinical implications, and current and future challenges in the management of patients with *GATA2* predispositions.

ROLE OF *GATA2* TRANSCRIPTION FACTOR IN HAEMATOPOIETIC AND NONHAEMATOPOIETIC TISSUES

GATA2 is a member of the *GATA* transcription factor family and is a master regulator of haematopoiesis and lymphatic angiogenesis by regulating target genes through occupying WGATAR DNA structure motifs with two zinc finger domains (ZF1 and ZF2).^{4,25,26} ZF1 controls protein-protein interactions, while ZF2 is critical for regulating transcription through protein-DNA binding.^{22,27} *GATA2* has a major role in the early embryonic haematopoietic specification through endothelial haematopoietic transition (EHT).²⁸⁻³² During postnatal haematopoiesis *GATA2* is expressed at high levels in HSCs and early haematopoietic progenitors,³¹⁻³⁵ and promotes myeloid-erythroid progenitor cell development^{11,21,27,36-38} (Figure 1A).

Furthermore, *GATA2* is expressed in the lymphatic endothelium, instigating fetal lymphatic vessel valve development and normal valve function in adults,^{24,39} and its mechanosensitive expression in endothelial cell compartment also implicates *GATA2* in angiogenesis and vascular integrity.^{25,40-42} Several single nucleotide polymorphisms (SNPs) of *GATA2* have been associated with coronary artery disease implying its putative role in arterial development; however, underlying molecular mechanisms involving *GATA2* are still poorly understood.^{24,43,44} Additionally, HSPCs and endothelial components, high *GATA2* protein levels were observed during fetal neurodevelopment,^{45,46} as well as in selected types of differentiated cells, including neurons, androgen receptor-expressing and endocrine cells,⁴⁷⁻⁴⁹ and macrophages.^{50,51}

EXISTING AND NEW EXPERIMENTAL MODELS TO STUDY *GATA2* FUNCTION

The role of *GATA2* gene as master regulator of haematopoietic system has been defined in 1994, when Orkin and colleagues showed that *Gata2*-KO mice died at 10.5 days post-coitum (dpc), due to the collapse of primitive and definitive haematopoiesis.^{28,29} Notably, mouse *Gata2*-null endothelial cells failed to produce HSCs because of impaired EHT.^{28,31-35} Formal demonstration of *GATA2* function within HSC development, proliferation and survival in adult haematopoiesis has been gleaned using *Gata2* +/- mice. Heterozygous *Gata2* +/- mice survive and show a reduced number of HSCs both in the embryo and within adult BM, and *Gata2*+/- HSCs are qualitatively defective.^{35,52} In




FIGURE 1 (A) Role of the GATA2 transcription factor during embryonal haematopoietic development and postnatal haematopoiesis. GATA2 plays a major role in the early embryonic haematopoietic specification through endothelial haematopoietic transition, maintenance of long-term haematopoietic stem cells (LT-HSC) and erythroid differentiation. The GATA2 transcriptional factor also instigates fetal lymphatic vessel valve development and normal valve function in adults, and its high expression in endothelial compartments also implicates its role in angiogenesis. During postnatal haematopoiesis GATA2 is expressed at high levels in haematopoietic stem cells (HSCs) and early haematopoietic progenitors and induces myeloid-erythroid progenitor cell development and differentiation through cell-specific transcription factor complexes. (B) Impact of GATA2 mutations and phenotype-modifying factors, and clinical phenotypes associated with GATA2 deficiency syndrome. Although different types of germline GATA2 variants have not been linked strongly to substantial phenotypes, some phenotypes seem to cluster within affected carrier families. AML, acute myeloid leukaemia; DCML, dendritic cell, monocyte, B- and NK- lymphoid deficiency; MDS, myelodysplastic syndrome.

addition, *in vivo* studies at single cell level revealed a GATA2 dose-dependent mechanism regulating HSC identity.^{53–55} Furthermore, Gata2 haploinsufficiency also reduces granulocytes-macrophage function but no other myeloid committed progenitors.⁵⁶ Of note, most recently, others and us have demonstrated a primary role of GATA2 in promoting EHT also in a human background using engineered pluripotent stem cells.^{28,30–35,57} Importantly, GATA2 is highly expressed in HSCs and its expression is tightly regulated by conserved cis-regulatory elements and other signalling pathways. Results of mouse studies based on targeted ablation of the far upstream Gata2–77 enhancer showed that it abrogates the multilineage differentiation potential of fetal liver progenitor cells without affecting HSC emergence,³⁸ which is diminished by the intronic +9.5 enhancer deletion^{35,39,58,59} (Figure 2). Furthermore, Notch signals tightly regulate the precise level of expression of GATA2 required for generation of HSCs in the embryonic aorta.^{60,61}

Zebrafish is another valuable model that have been extensively used to study the function of GATA2 in haematopoiesis. A genome duplication event in early teleosts generated two Gata2 paralogs in the zebrafish genome: Gata2a and

Gata2b.⁶² Previous studies have indicated that Gata2a is implicated in lymphovascular development with some expression in HSPCs in adult haematopoiesis,^{63–65} whereas Gata2b is mainly expressed in HE cells that give rise to HSCs in adult haematopoiesis.⁶⁶ In addition, Gata2a mutant for the conserved enhancer i4, corresponding to the described +9.5 enhancer in the mouse Gata2 locus, revealed that Gata2a is required upstream of Gata2b, regulating Runx1 and Gata2b expression in the haemogenic endothelium⁶⁷ (Figure 2). Recent transcriptomic analyses have shown that Gata2b loss impaired progression of the myeloid transcriptional programme while increasing the lymphoid programme in haematopoietic progenitors.^{68,69} Altogether these findings suggest that mammalian Gata2 functions are divided among gata2a and gata2b in zebrafish.

Overall, these findings have contributed greatly to our understanding of the role of GATA2 in embryonic and adult haematopoiesis. However, Gata2 +/- mice do not develop MDS and AML, probably due to the short lifespan of mice, the different external stressor factors or the absence of concurrent somatic lesions as observed in GATA2-related MDS patients. Furthermore, there is still lack of a knock-in mouse




FIGURE 2 Schematics of different strategies of disease modelling GATA2 deficiency in vivo. (A) Zebrafish; (B) genetically engineered modified mouse (GEMM); (C) CD34⁺ genetic edited cells transplanted to immunodeficient mice; (D) in vitro induced pluripotent stem (iPS) cells derived from patients and (E) genome edited iPS cells. (D and E) are used for in vitro disease modelling (left). Experimental readout of the disease models (right).

model, which allows the overexpression of GATA2 mutant protein, mimicking the haematological manifestations observed in human GATA2 carriers. Therefore, there is a clear need for the development of better faithful mouse models of GATA2 deficiency, including patient-derived xenograft (PDX), to mimic better this complex disease. Nowadays, there are no PDX studies focusing on patients carrying germline GATA2 mutations. Generally, the establishment of human preclinical models by xenotransplantation of primary MDS cells in immunodeficient mice represent a bottleneck that hampers research of the mechanism understanding this disease. During the last decade, several laboratories have tested different approaches including intratibial injection in NSG (NOD-Scid-IL-2Rcnnull) or NSG-S (NSG/IL3/GM-CSF/hSFCF), cotransplantation with patient-derived or normal mesenchymal stem cell (MSC).⁷⁰ However, these methods showed low efficiency and poor engraftment rate, with a skew towards the lymphoid lineage.^{71–73} The

biological reasoning behind the poor engraftment of MDS primary cells remains unclear and might be related to both the specific requirements for environmental factors and/or the intrinsic biological characteristic of individual samples. This limitation might be overcome by the generation of a humanized BM-MSC-derived ossicles (ectopic bone organoid composed of human bone, stroma, and haematopoietic tissue) that provides a human microenvironment.⁷⁴ A more consistent outcome was achieved by using MISTRG mice, a humanized strains expressing human M-CSF, IL-3, GM-CSF, SIRP alpha and thrombopoietin at physiological level.⁷⁵ The selection of the most suitable mouse model can significantly affect the outcome of the research findings. The pivotal question that remains unanswered is which mouse model should be used to study GATA2 deficiency. Another limitation for the development of mouse disease models is the genetic heterogeneity and the low prevalence of GATA2 deficiency that limits the access to patient primary cells. A

possible solution could be the generation of GATA2 deficiency preclinical mouse models using engineered human haematopoietic CD34+ cells (both from cord blood and mobilized peripheral blood). The ongoing improvement of CRISPR/Cas9 genomic engineering technologies enable the manipulation of genes in primary CD34+ cells, facilitating the development of preclinical models to study the molecular mechanisms and the clonal evolution of haematological diseases^{76–78} (Figure 2). Furthermore, those models would be fundamental tools to identify genetic subtype that are sensitive or resistant to therapeutic agents. In parallel, the induced pluripotent stem cells (hiPSCs)-based approach represents an alternative cellular platform for mechanistic studies and drug screening.^{79–82} Recently, we reported the generation of human iPSC carrying two of the most recurrent GATA2 mutations in paediatric MDS patients.⁸³ The availability of differentiated haematopoietic progenitor cells from iPSCs carrying GATA2 mutations will allow a comprehensive investigation of effects of these mutations as well as of secondary oncogenic somatic alterations (Figure 2). Indeed, hiPSC model offers the possibility to study the stepwise progression of GATA2-related MDS in vitro through the sequential introduction of secondary oncogenic genetic lesions by CRISPR/Cas9 gene editing, as already shown for adult AML.⁸⁴ Importantly, the iPSC-based approach allows the characterization of transcriptional programs driving specific stage malignant transition and the identification of possible prognostic markers for early therapeutic targeting (Figure 2).

TYPES OF DISEASE-CAUSING GERMLINE GATA2 MUTATIONS

Hereditary genetic alterations disrupting *GATA2* expression and protein function are pivotal in leukemogenesis by sabotaging normal haematopoiesis leading to GATA2 deficiency and subsequent myeloid malignancies. Approximately one-third of all germline *GATA2* variants are passed on through autosomal dominant inheritance (familial), while at least two-thirds of the mutations occur de novo.^{4,85,86} Mutational landscape of GATA2 deficiency includes a steadily increasing number of variants with approximately 500 published cases harbouring roughly 180 different familial or de novo germline mutations and partial or whole gene deletions.^{11,20,87} The majority of reported pathogenic or probably pathogenic germline variants are inactivating (null) or loss-of-function (LOF) resulting in haploinsufficiency (~60% of all GATA2 deficient cases) either through truncating (nonsense), frameshift or splicing mutations and deletions.^{1,19,22,27,88–91} These confirmed germline variants along with less common in-frame deletions and insertions are scattered throughout the coding region of *GATA2*.^{3,21}

In addition to variants leading to premature translation termination prior or within ZF2, missense variants within ZF2 represent a large proportion of germline *GATA2* variants (~30%) instigating LOF via disrupting

protein–protein interactions^{21,92} and DNA binding.^{1,10,90,92} Monoallelic missense mutations of the ZFs have been reported mostly, albeit not exclusively, within the extended ZF2 domain with only a few confirmed cases of germline variants affecting ZF1. Intriguingly, unlike germline LOF *GATA2* variants, somatic *GATA2* mutations of adult AML affecting the ZFs occur with a preference for ZF1 and can exhibit gain-of-function (GOF) effects.^{22,93,94} Germline variants in ZF1, such as p.Ala318Thr,⁶⁵ p.His313Tyr and p.Leu315Pro¹⁷ are recognized as LOF alterations and in most cases associated with paediatric MDS and accompanying symptoms of underlying GATA2 deficiency. Notably, a novel germline missense mutation in ZF1 (p.Asn317Ser) was recently reported by Rüttsche and colleagues in a patient with JAK2 positive primary myelofibrosis (PM) and pancytopenia, although the role of GATA2 in the pathogenesis of PM remains unclear.⁹⁵

Recurrent missense mutations in the extended ZF2 region diminishing DNA binding, including hotspot variants p.Thr354Met,^{1,6,10,96–98} p.Arg396Trp/Gln^{3–5,17,98–101} and p.Arg398Trp,^{6,9,10,98,101} have been reported across a number of individuals and families and seem to be almost exclusively familial. Interestingly, similar to somatic *GATA2* mutations p.Leu359Val^{92,93} and p.Arg307Trp,¹⁰² the germline mutations p.Thr354Met and p.Cys373Arg were both reported to exhibit gain of binding affinity to a GATA2 partner protein (PU.1 encoded by *SPI1* gene). This might suggest an additional mechanism to LOF driving leukemogenesis, namely context-dependent gain of function.^{20,92}

Apart from missense variants, there are a few reports of synonymous *GATA2* mutations in a handful of GATA2-deficient cases to date. Despite the unaltered amino acid composition, the variants result in RNA degradation and can be categorized as null alleles. The variant p.Thr117=, first described by Wehr and colleagues,^{103–105} along with four additional mutations, namely p.Leu217=, p.Gly327=, p.Ala341 = and p.Phe472=, reported by Kozyra and colleagues,¹⁰⁴ was found to strongly alter splicing and induce selective loss of messenger RNA.^{20,104,105} Although substantial phenotypic changes may support the putative role of synonymous *GATA2* mutations, sequencing of *GATA2* mRNA to confirm monoallelic loss and in silico analyses are essential to assess the actual impact of these seemingly innocuous, albeit potentially damaging variants on *GATA2* expression for each individual case.^{20,104}

Regulatory variants (in approximately 10% of patients) constitute an important group of germline mutations affecting the *GATA2* intronic +9.5 enhancer site and thus leading to haploinsufficiency via decreased *GATA2* expression in HSPCs. Consequently, damaging mutations and deletions of intron 4 (NM_032638 isoform) perturb the dose-dependent transactivation activity of the *Gata2* intronic enhancer disrupting haematopoietic cell development and cell differentiation fates.^{35,38,58,59} Interestingly, no germline variants of the distant upstream *Gata2*–77 enhancer site have been described to date, although current clinical platforms (panel and exome sequencing) do not account for such regulatory

regions. Future studies using whole genome sequencing have the potential to uncover undefined causes of GATA2 deficiency, that is, in hitherto unknown regulatory regions.

Rare cases of whole gene deletions,^{97,106,107} in-frame deletions^{1,6,9,98} and missense mutations located outside of relevant protein domains^{6,108,109} have also been reported, although data and functional studies on their putative impact (presumably LOF) are still absent.⁸⁹ Recently, a novel type of germline in-frame GATA2 variants has been reported by Cavalcante de Andrade Silva and colleagues in a patient with characteristic features of GATA2 deficiency, including bilateral lower limb lymphoedema, haematological manifestations, and recurrent infections. The familial in-frame insertion of nine amino acids between ZF1 and ZF2 increased the spacing between the two ZFs abrogating target gene regulation and cell differentiation.¹¹⁰

CLINICAL PHENOTYPES ASSOCIATED WITH GATA2 DEFICIENCY

Detailed description of the clinical presentations of GATA2 deficiency syndrome is beyond the scope of this review, therefore we refer to comprehensive reviews discussing GATA2-associated phenotypes^{20,89} and previously published large cohort studies.^{4,17}

Myeloid malignancy is the most common phenotype associated with germline GATA2 mutations, manifesting in roughly 80% of reported carriers at a median age of approximately 20 years,^{1,4,5,20,89} (Figure 1B). GATA2 deficiency is considered the most common germline predisposition in paediatric MDS, accounting for 15% of cases with MDS with excess blasts, and 7% of overall paediatric MDS within the co-operative European Working Group of MDS in Childhood (EWOG-MDS) cohort of 426 patients published by Wlodarski and colleagues.⁴ These numbers were validated in a larger cohort of 669 patients from the EWOG-MDS registry, where GATA2 deficiency was detected in 7% of MDS cases and was mutually exclusive with germline *SAMD9/SAMD9L* mutations (another driver of paediatric marrow failure and MDS) which accounted for 8%.¹¹¹

Immunological phenotypes of GATA2 predisposition most commonly present as cellular immunodeficiencies with subsequent recurrent or atypical mycobacterial, viral, and fungal infections and autoimmunity. Immune dysfunction is often the initial presentation in this patient population; however, pre-existing immunodeficiency may also be observed retrospectively in more than half of the cases with myeloid malignancy and thus is strongly suggestive for GATA2-related MDS/AML.^{22,89} Prominent clinical manifestations of GATA2 deficiency also include repeatedly observed pulmonary alveolar proteinosis (PAP), and interstitial pulmonary diseases¹¹² and high incidence of solid tumours and precancerous lesions with the majority of the cancers arising from underlying viral infections, particularly HPV and EBV.^{3,6,15,100,113}

Apart from general symptoms including fever, fatigue and weight loss, further extra-haematological phenotypes of GATA2 deficiency encompass premature birth, developmental delays and congenital malformations,^{5,17,56,114,115} and high incidence of primary lymphedema and lymphadenopathy in the GATA2 deficient patient population underlying the crucial role of GATA2 in lymphatic angiogenesis and lymphatic valve development.⁹⁷

GENOTYPE-PHENOTYPE CORRELATIONS IN GATA2 DEFICIENCY

Despite the rising number of reported cases with GATA2 deficiency, different types of germline GATA2 variants have not been linked strongly to substantial phenotypes, clinical outcomes or age of onset, although some phenotypes seem to cluster within affected carrier families (Figure 1B). Some analyses have shown missense GATA2 mutations to be associated with increased rates of myeloid malignancies compared to nonsense and frameshift variants^{12,17,86} with a predominance of leukaemia in patients harbouring p.Thr354Met.²⁰ However, this association was not confirmed in a cohort of 173 European MDS patients with germline GATA2 variants, examined on behalf of the GATA2 HuMo consortium; cases with null alleles (encompassing nonsense, frameshift truncating, splice site, whole gene deletion and synonymous - RNA deleterious variants) had a higher prevalence of high-risk MDS (including leukaemia) in comparison to missense mutation carriers (unpublished observations of the EWOG-MDS study group). Recurrent or severe infections and underlying cellular immunodeficiencies have been linked to variants leading to premature translation termination and deletions,^{12,86} although interestingly, missense mutations p.Arg398Trp and p.Arg396Gln, have also recently been associated with immunodeficiency by Homan and colleagues based on analysis of reported cases.²⁰

Emberger syndrome has been exclusively reported in cases with regulatory, premature termination or LOF missense variants diminishing DNA binding and transactivation activity (p.Arg361Leu, p.Cys373Arg, p.Arg396Gln), implying the crucial role of haploinsufficiency in lymphedema development.^{17,20,24,86,92} Underlying molecular mechanism for normal lymphatic vessel valve development and defects of the lymphatic vasculature in GATA2 deficiency was first proposed by Kazenwadel and colleagues.²⁴ They demonstrated that GATA2 levels in lymphatic endothelial cells are regulated via mechanic stimuli, including oscillatory fluid flow¹¹⁶ and extracellular matrix-induced tension⁴² driving valve morphogenesis and vessel sprouting, respectively. Stimuli-dependent expression and cell-specific transcription factor complexes of GATA2 in lymphatic endothelial cells seem to be profoundly impacted by haploinsufficiency compared to HSPCs.

Based on a handful of cases, large, whole gene deletions and losses of chromosome 3q21.3 resulting in GATA2

haploinsufficiency have been linked to dysmorphisms, developmental and neurological defects, monocytopenia and subsequent infections.^{12,91,97}

Regulation and transcription factors interacting with GATA2 vary greatly in selected biological systems and in the steady state versus stress, providing a possible explanation to phenotype–genotype clustering in GATA2 deficiency. Although it has been noted that substantial clinical presentations and defects of certain organs are related to distinct types of GATA2 variants, *in vitro* studies on GATA2 function in different cellular contexts and processes are required to provide novel insight to underlying molecular mechanisms of phenotypic complexity.^{20,21,86}

SOMATIC ABERRATIONS IN MYELOID MALIGNANCIES WITH GATA2 PREDISPOSITION

There are a number of recurrent cytogenetic aberrations and somatic mutations in a host of genes that occur commonly with GATA2 deficiency and subsequent myeloid malignancies. Monosomy 7 is the most frequently described clonal cytogenetic aberration. It has been reported in nearly half of the GATA2 deficient cases with associated myeloid malignancies²⁰ and together with the deletion of 7q¹⁷ and unbalanced translocation der(1;7)(q10;p10)^{3,14,117} uniformly result in the monoallelic loss of chromosome 7q conferring poor prognosis.^{89,118} Among paediatric MDS with monosomy 7, 37% of cases were found to carry germline GATA2 mutations; this association is even more striking in adolescents with monosomy 7 where GATA2 deficiency is found in 72% of patients.^{4,118,119}

Similarly, the association between der(1;7) and GATA2 deficiency was reiterated in a recent study by Kozyra and colleagues, demonstrating the majority (73%) of primary MDS with der(1;7) have an underlying GATA2 deficiency.¹²⁰ Isolated trisomy 8 is the second most common aneuploidy in GATA2 mutation carriers, occurring in approximately 20% of the cases.^{1,3–6,17,20,98} Other cytogenetic events, such as trisomy 21,^{1,97,121} have also been encountered alone (isolated) or in combination with other aberrations; however, due to the lack of routine screening their prevalence is largely unknown to date. Contrary to MDS of adulthood, loss of 5q and complex karyotypes are generally not reported in GATA2 deficiency.^{11,22}

Recurrent somatic mutations in *SETBP1*, *ASXL1*, *CBL*, *EZH2*, *KRAS/NRAS*, *JAK3*, *STAG2*, *RUNX1*, and *PTPN11* and *STAG2* have been described in cases with GATA2-driven myeloid malignancies.^{88,96,101,106,122–131} LOF *ASXL1* mutations are reported in approximately one-third of all patients with AML/MDS and similarly to *SETBP1* variants, are strongly linked to monosomy 7 and thus associated with a more advanced disease state.^{96,98} Interestingly, single-cell level analyses reported by Pastor Loyola and colleagues revealed a non-random acquisition of these secondary events, implying monosomy 7 as an early somatic event in the MDS founding clone, followed by the acquisition of concomitant

SETBP1 and *ASXL1* mutations.^{89,132} Unlike in cases with germline *CEBPA*, *DDX41* and *RUNX1* predispositions,^{103–105} biallelic mutations are uncommon as somatic GATA2 mutations mainly within ZF1 seem to be rare secondary events in GATA2-driven myeloid neoplasia.^{20,127,133}

Similar to biological and environmental stresses, commonly seen somatically mutated genes and recurrent cytogenetic alterations are putative “stressor events” that may constitute pathogenic triggers for clonal evolution and subsequent disease progression/evolution to AML.²¹ Therefore, there is a strong, and today still unmet need for comprehensive screening of concurrent somatic aberrations in GATA2 deficiency, especially in individuals and families with unexpected clinical presentations and incomplete penetrance.

THERAPEUTIC STANDARD OF CARE

Despite the increasing number of cases with GATA2 deficiency syndrome, currently there are no comprehensive guidelines and recommendations on the diagnosis and clinical management of individuals and families carrying germline GATA2 mutations. Similar to other germline cancer predisposition syndromes, suspicion of GATA2 deficiency arises in cases with unusually early age of onset of myeloid malignancies, particularly MDS/AML, but positive family history may also be evocative.¹³⁴ Although in some patients MDS/AML develops without pre-existing extra-haematopoietic phenotypes, others may show progressive symptoms indicative for GATA2 deficiency, such as cytopenias, generalized warts and monocytopenia, mycobacterial infections, recurrent viral (predominantly HPV) infections, and lymphedema.^{4,86,135} Cytogenetic testing of BM biopsy samples in cases with MDS/AML or unexplained cytopenias may be informative, as concurrent monosomy 7 and trisomy 8 can also point towards GATA2 deficiency.⁸⁹

Early diagnosis of GATA2 deficiency based on clinical presentation and/or genetic testing for germline GATA2 mutations (with conventional bidirectional Sanger sequencing or next generation sequencing methods) is pivotal in avoiding non-curative therapies and especially immunosuppression due to underlying HSPC defects and immunodeficiency.⁸⁹ Patients with high risk of evolution to advanced MDS or AML and/or high-risk karyotypes, such as monosomy 7, should undergo timely HSCT with selected conditioning regimens. Patients with stable disease (e.g. MDS with refractory cytopenia of childhood), without progressing immunodeficiencies underlying recurrent infections, transfusion-dependency and MDS with karyotypic aberrations or dysplasia may qualify for the watch and wait approach, although progressive disease can be expected over time in the majority of cases.^{3,11,89,136–138} General recommendations for surveillance include frequent evaluation of complete blood counts, annual BM biopsies with cytogenetic testing, analysis of lymphocyte subsets and immunoglobulins, and screening for subclinical presentations of pulmonary disorders (predominantly PAP) and (HPV- or




FIGURE 3 Isolation of haematopoietic stem cells (HSCs) of a *GATA2*mut patient and gene correction using the CRISPR/Cas9 system. The induced pluripotent stem cell (iPSC) function can be further evaluated after transplantation into mouse model.

EBV-associated) cancers as part of yearly skin and gynaecological examinations.⁸⁶

Currently, allogeneic HSCT is the only curative approach for patients with *GATA2* deficiency. There is consensus that in high-risk cases, the ideal point in time for pre-emptive HSCT is during the hypocellular phase of MDS prior to severe complications, such as invasive infections or evolution to MDS-EB and AML.^{4,11,22,88,89,113,136} Myeloablative conditioning regimens for HSCT are the preferred standard approach in paediatric MDS with *GATA2* predisposition, but reduced intensity conditioning regimens have also been successfully used in some cases.^{4,11,86,89,121,139} Based on the results of EWOG-MDS cohort study, overall outcomes were not influenced by the presence of germline *GATA2* variants with a comparably favourable 5-year overall survival of 66% in patients with MDS who had already acquired monosomy 7. Rates of infectious complications were also comparable to the control *GATA2* wild-type group (66% vs. 61%),⁴ but despite the non-inferior results, HSCT in *GATA2* deficiency remains challenging due to underlying immunodeficiencies and comorbidities threatening the outcome of HSCT.^{86,137} Interestingly, Hoffman and colleagues recently reported a higher incidence of thrombotic events and neurological complications in a cohort of patients with *GATA2*-driven paediatric MDS undergoing HSCT with myeloablative conditioning, although graft versus host disease (GVHD), graft failure and treatment related mortality rates were comparable to patients with non-*GATA2*-driven MDS/AML.¹⁴⁰

Considering highly variable phenotypes and incomplete penetrance of *GATA2* deficiency, genetic testing of inherited *GATA2* variants should be performed in family members to identify asymptomatic carriers.²⁰ Although data and recommendations on early HSCT in phenotypically “silent” cases are still absent to date, baseline BM aspirate evaluation

of healthy individuals carrying *GATA2* variants is recommended by the EWOG-MDS group to assess *GATA2*-related cytogenetic aberrations.^{86,88} Similar to patients with stable disease, further management of asymptomatic carriers may include evaluation of complete blood counts, pulmonary function tests and surveillance for malignancy and immunodeficiencies.^{88,141} Notably, critical role of screening for inherited variants in relatives is also becoming generally recognized during HSCT donor selection in order to avoid donor-derived myeloid malignancies conferring dismal outcome.^{20,142}

POTENTIAL NOVEL THERAPIES

GATA2-related MDS/AML constitute a complex disorder with a profound impact on the quality of life of patients and their life expectancy. Due to the phenotypic diversity, clinical overlap, and the evolving phenotype of this disease, achieving a timely diagnosis is often difficult. This holdup has a direct impact on patient's management. The only curative option for these patients is allogeneic HSCT, usually performed in the setting of advanced MDS or severe immunodeficiency. The overall outcome after HSCT is favourable for the early stages of haematological disease but declines considerably in patients with advanced MDS. In addition, the lack of suitable donor and associated mortality and morbidity can hinder this procedure in a number of patients. Correction of patients' HSCs by gene therapy could represent a promising alternative to allogeneic HSCT, due to the proliferative advantage of corrected cells (Figure 3). This phenomenon has been recently described in one unique case, in whom spontaneous somatic genetic rescue in *GATA2* gene conferred selective advantage of the corrected HSCs and

annulled the effect of pathogenic *GATA2* mutation.¹⁴³ These findings strongly indicate that having few corrected HSCs might be sufficient to restore haematopoiesis in *GATA2* carriers. It is important to highlight that the expression of *GATA2* gene is tightly regulated in HSCs and during leukaemia progression. Therefore, classical lentiviral transgenic approaches do not represent the best option as gene therapy method to treat *GATA2* deficiency. Advanced gene editing technology via homologous recombination (HR) has paved the way to the development of precision medicine and outcome-driven therapy for individual patients.^{78,144,145} This allows the specific correction of the mutated gene, maintaining the physiological expression of the gene and eliminating the integration of exogenous DNA material elsewhere. Moreover, gene editing based on CRISPR/Cas9 and large HR donor deliver by adeno-associated viral vector of serotype 6 (rAVV6) has already revealed promising clinical results, as recently shown in haematological diseases such as sickle cell disease and pyruvate kinase deficiency.^{76,144,146,147}

Based on these advances we can speculate that the optimization of a repair mechanism by large HR donor templates covering different exons could provide treatment for a substantial number of *GATA2* patients allowing effective and sustainable translation in the clinical arena (Figure 3). Importantly, recurrent somatic mutations in MDS driver genes (i.e. *SETBP1*, *ASXL1*, *STAG2* and *RAS* pathways) has been identified by us and others in *GATA2*-MDS patients.^{88,96,101,106,122-130} Therefore, a preliminary genomic screening for additional somatic mutations should be implemented as standard procedure for each *GATA2* deficient patient. This may serve as prognostic markers predicting the risk of relapse, and thus be crucial in guiding treatment strategy. Finally, a possible technical obstacle for clinical application of gene editing correction of *GATA2* mutations is the off-target effects (OTEs) that might occur in undesired parts of the genome. Therefore, detection of OTEs with screening strategies, such as GUIDE-seq or CIRCLE-seq,^{148,149} should be used before any clinical translation of this gene therapy approach.

CONCLUSION

GATA2 deficiency is a monogenic disorder with complex clinical manifestations and a very high propensity for MDS/AML development. Carriers of *GATA2* mutations show nearly complete life-time penetrance towards the development of myeloid neoplasia; however, it is not clear what factors (genetic, epigenetic, or inflammatory) modify the phenotype leading to variable penetrance observed for identical mutations. Due to the phenotypic diversity, clinical overlap and evolving phenotype of this disease, a timely diagnosis is often difficult to achieve. Therefore, a crucial unmet need for novel, genotype-specific, more efficacious therapies for *GATA2* deficient patients remain. Recently, Catto and colleagues suggested that early recovery of haematopoiesis in *GATA2* deficiency either by transplant or potentially by gene

therapy may be beneficial for haematopoiesis and to prevent other clinical complications.¹⁴³

In this context, with the breakthroughs in CRISPR/Cas9 technology, it is an imaginable scenario where *GATA2* carriers at early stage of the disease can be actively assisted by an innovative tailored and precise gene-based treatment. The reinfusion of corrected autologous HSCs would represent a promising and less toxic alternative treatment for *GATA2*-related MDS. However, a multidisciplinary effort is still needed to establish the clonal origin of leukemogenesis in *GATA2* carriers in order to select the appropriate time frame to treat these patients by gene editing.

AUTHOR CONTRIBUTIONS

LK, DRM, CB and AG wrote the manuscript, OM-B prepared figures and reviewed the manuscript, EK, AC, AB, MWW reviewed and edited the manuscript.

ACKNOWLEDGEMENTS

This work was supported by ERA PerMed *GATA2*-HuMo Funding Mechanism (Spain: Acció instrumental de SLT011/18/00006 of the Department of Health of the Government of Catalonia, to AG and AB; Hungary: ED-18-1-2019-001 grant from the National Research, Development and Innovation Office to CB; and Germany: German Federal Ministry of Education and Research (BMBF) 2018-123/01KU1904 to MWW), ÚNKP-21-2-I-SE-21 and Hungarian National Academy of Scientist Education grant to KL, TKP2021-NVA-15, TKP2021-EGA-24 and EU's Horizon 2020 research and innovation programme under grant agreement no. 739593 and Elixir Hungary to CB, MSCA No 101029927-sc*GATA2*track (H2020-MSCA-IF-2020) to OM-B, the Spanish Ministry of Economy, Industry, and Competitiveness (MINECO PID2020-15591RB-I00), La Marató de TV3 (202001-32), FPS Grant 2018 by Fondazione Pisana per la Scienza ONLUS and CERCA Programme/Generalitat de Catalunya for institutional support to AG, Vera and Joseph Dresner Foundation, Evans MDS Foundation, American Lebanese Syrian Associated Charities, and BMBF MyPred 01GM1911A to MWW. Open access funding enabled and organized by ProjektDEAL.

COMPETING INTEREST


The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this study.

DATA AVAILABILITY STATEMENT

All data used in this manuscript was collected using the PubMed database (accessed: 20 April 2022).

ORCID

Lili Kotmayer  <https://orcid.org/0000-0002-5089-7659>

Damia Romero-Moya  <https://orcid.org/0000-0001-9947-3577>

Oskar Marin-Bejar  <https://orcid.org/0000-0002-6889-6566>

Emilia Kozyra  <https://orcid.org/0000-0003-1107-8818>
 Albert Català  <https://orcid.org/0000-0003-0133-1752>
 Anna Bigas  <https://orcid.org/0000-0003-4801-6899>
 Marcin W. Wlodarski  <https://orcid.org/0000-0001-6638-9643>
 Csaba Bödör  <https://orcid.org/0000-0002-0729-692X>
 Alessandra Giorgetti  <https://orcid.org/0000-0001-5803-3567>

REFERENCES

- Hahn CN, Chong CE, Carmichael CL, Wilkins EJ, Brautigan PJ, Li XC, et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. *Nat Genet*. 2011;43(10):1012–7.
- Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of Tumours of Haematopoietic and lymphoid tissues. 4th ed. Bosman FT, Jaffe ES, Lakhani SR, Ohgaki H, editors. Lyon: International Agency for Research on Cancer; 2017.
- Spinner MA, Sanchez LA, Hsu AP, Shaw PA, Zerbe CS, Calvo KR, et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. *Blood*. 2014;123(6):809–21.
- Wlodarski MW, Hirabayashi S, Pastor V, Stary J, Hasle H, Masetti R, et al. Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. *Blood*. 2016;127(11):1387–97. quiz 518.
- Pasquet M, Bellanne-Chantelot C, Tavitian S, Prade N, Beaupain B, Larochelle O, et al. High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia. *Blood*. 2013;121(5):822–9.
- Hsu AP, Sampaio EP, Khan J, Calvo KR, Lemieux JE, Patel SY, et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. *Blood*. 2011;118(10):2653–5.
- Ostergaard P, Simpson MA, Connell FC, Steward CG, Brice G, Woollard WJ, et al. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). *Nat Genet*. 2011;43(10):929–31.
- Emberger JM, Navarro M, Dejean M, Izarn P. Deaf-mutism, lymphedema of the lower limbs and hematological abnormalities (acute leukemia, cytopenia) with autosomal dominant transmission. *J Genet Hum*. 1979;27(3):237–45.
- Bigley V, Haniffa M, Doulatov S, Wang XN, Dickinson R, McGovern N, et al. The human syndrome of dendritic cell, monocyte, B and NK lymphoid deficiency. *J Exp Med*. 2011;208(2):227–34.
- Dickinson RE, Griffin H, Bigley V, Reynard LN, Hussain R, Haniffa M, et al. Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency. *Blood*. 2011;118(10):2656–8.
- Sahoo SS, Kozyra EJ, Wlodarski MW. Germline predisposition in myeloid neoplasms: unique genetic and clinical features of GATA2 deficiency and SAMD9/SAMD9L syndromes. *Best Pract Res Clin Haematol*. 2020;33(3):101197.
- Mir MA, Kochuparambil ST, Abraham RS, Rodriguez V, Howard M, Hsu AP, et al. Spectrum of myeloid neoplasms and immune deficiency associated with germline GATA2 mutations. *Cancer Med*. 2015;4(4):490–9.
- Hsu AP, McReynolds LJ, Holland SM. GATA2 deficiency. *Curr Opin Allergy Clin Immunol*. 2015;15(1):104–9.
- Ganapathi KA, Townsley DM, Hsu AP, Arthur DC, Zerbe CS, Cuellar-Rodriguez J, et al. GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia. *Blood*. 2015;125(1):56–70.
- Mace EM, Hsu AP, Monaco-Shawver L, Makedonas G, Rosen JB, Dropulic L, et al. Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56(bright) subset. *Blood*. 2013;121(14):2669–77.
- Novakova M, Zaliova M, Sukova M, Wlodarski M, Janda A, Fronkova E, et al. Loss of B cells and their precursors is the most constant feature of GATA-2 deficiency in childhood myelodysplastic syndrome. *Haematologica*. 2016;101(6):707–16.
- Donadieu J, Lamant M, Fieschi C, de Fontbrune FS, Caye A, Ouachee M, et al. Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients. *Haematologica*. 2018;103(8):1278–87.
- Rio-Machin A, Vulliamy T, Hug N, Walne A, Tawana K, Cardoso S, et al. The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants. *Nat Commun*. 2020;11(1):1044.
- Hsu AP, Johnson KD, Falcone EL, Sanalkumar R, Sanchez L, Hickstein DD, et al. GATA2 haploinsufficiency caused by mutations in a conserved intronic element leads to MonoMAC syndrome. *Blood*. 2013;121(19):3830–7. S1–7.
- Homan CC, Venugopal P, Arts P, Shahrin NH, Feurstein S, Rawlings L, et al. GATA2 deficiency syndrome: a decade of discovery. *Hum Mutat*. 2021;42(11):1399–421.
- Bresnick EH, Jung MM, Katsumura KR. Human GATA2 mutations and hematologic disease: how many paths to pathogenesis? *Blood Adv*. 2020;4(18):4584–92.
- Hirabayashi S, Wlodarski MW, Kozyra E, Niemeyer CM. Heterogeneity of GATA2-related myeloid neoplasms. *Int J Hematol*. 2017;106(2):175–82.
- Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. *Blood*. 2013;122(22):3616–27. quiz 99.
- Kazenwadel J, Betterman KL, Chong CE, Stokes PH, Lee YK, Secker GA, et al. GATA2 is required for lymphatic vessel valve development and maintenance. *J Clin Invest*. 2015;125(8):2979–94.
- Linnemann AK, O'Geen H, Keles S, Farnham PJ, Bresnick EH. Genetic framework for GATA factor function in vascular biology. *Proc Natl Acad Sci USA*. 2011;108(33):13641–6.
- Dore LC, Chlon TM, Brown CD, White KP, Crispino JD. Chromatin occupancy analysis reveals genome-wide GATA factor switching during hematopoiesis. *Blood*. 2012;119(16):3724–33.
- Katsumura KR, Bresnick EH, Group GFM. The GATA factor revolution in hematology. *Blood*. 2017;129(15):2092–102.
- Tsai FY, Keller G, Kuo FC, Weiss M, Chen J, Rosenblatt M, et al. An early haematopoietic defect in mice lacking the transcription factor GATA-2. *Nature*. 1994;371(6494):221–6.
- Tsai FY, Orkin SH. Transcription factor GATA-2 is required for proliferation/survival of early hematopoietic cells and mast cell formation, but not for erythroid and myeloid terminal differentiation. *Blood*. 1997;89(10):3636–43.
- Castano J, Aranda S, Bueno C, Calero-Nieto FJ, Mejia-Ramirez E, Mosquera JL, et al. GATA2 promotes hematopoietic development and represses cardiac differentiation of human mesoderm. *Stem Cell Reports*. 2019;13(3):515–29.
- Zhou Y, Zhang Y, Chen B, Dong Y, Zhang Y, Mao B, et al. Overexpression of GATA2 enhances development and maintenance of human embryonic stem cell-derived hematopoietic stem cell-like progenitors. *Stem Cell Reports*. 2019;13(1):31–47.
- Kang H, Mesquita WT, Jung HS, Moskvina OV, Thomson JA, Slukvin II. GATA2 is dispensable for specification of hemogenic endothelium but promotes endothelial-to-hematopoietic transition. *Stem Cell Reports*. 2018;11(1):197–211.
- Menendez-Gonzalez JB, Vukovic M, Abdelfattah A, Saleh L, Almotiri A, Thomas LA, et al. Gata2 as a crucial regulator of stem cells in adult hematopoiesis and acute myeloid leukemia. *Stem Cell Reports*. 2019;13(2):291–306.
- de Pater E, Kaimakis P, Vink CS, Yokomizo T, Yamada-Inagawa T, van der Linden R, et al. Gata2 is required for HSC generation and survival. *J Exp Med*. 2013;210(13):2843–50.

35. Gao X, Johnson KD, Chang YI, Boyer ME, Dewey CN, Zhang J, et al. Gata2 cis-element is required for hematopoietic stem cell generation in the mammalian embryo. *J Exp Med*. 2013;210(13):2833–42.
36. Persons DA, Allay JA, Allay ER, Ashmun RA, Orlic D, Jane SM, et al. Enforced expression of the GATA-2 transcription factor blocks normal hematopoiesis. *Blood*. 1999;93(2):488–99.
37. Bresnick EH, Katsumura KR, Lee HY, Johnson KD, Perkins AS. Master regulatory GATA transcription factors: mechanistic principles and emerging links to hematologic malignancies. *Nucleic Acids Res*. 2012;40(13):5819–31.
38. Johnson KD, Hsu AP, Ryu MJ, Wang J, Gao X, Boyer ME, et al. Cis-element mutated in GATA2-dependent immunodeficiency governs hematopoiesis and vascular integrity. *J Clin Invest*. 2012;122(10):3692–704.
39. Lim KC, Hosoya T, Brandt W, Ku CJ, Hosoya-Ohmura S, Camper SA, et al. Conditional Gata2 inactivation results in HSC loss and lymphatic mispatterning. *J Clin Invest*. 2012;122(10):3705–17.
40. Mammoto A, Connor KM, Mammoto T, Yung CW, Huh D, Aderman CM, et al. A mechanosensitive transcriptional mechanism that controls angiogenesis. *Nature*. 2009;457(7233):1103–8.
41. Khandekar M, Brandt W, Zhou Y, Dagenais S, Glover TW, Suzuki N, et al. A Gata2 intronic enhancer confers its pan-endothelial-specific regulation. *Development*. 2007;134(9):1703–12.
42. Frye M, Taddei A, Dierkes C, Martinez-Corral I, Fielden M, Ortsater H, et al. Matrix stiffness controls lymphatic vessel formation through regulation of a GATA2-dependent transcriptional program. *Nat Commun*. 2018;9(1):1511.
43. Muiya NP, Wakil S, Al-Najai M, Tahir AI, Baz B, Andres E, et al. A study of the role of GATA2 gene polymorphism in coronary artery disease risk traits. *Gene*. 2014;544(2):152–8.
44. Connelly JJ, Wang T, Cox JE, Haynes C, Wang L, Shah SH, et al. GATA2 is associated with familial early-onset coronary artery disease. *PLoS Genet*. 2006;2(8):e139.
45. Nardelli J, Thiesson D, Fujiwara Y, Tsai FY, Orkin SH. Expression and genetic interaction of transcription factors GATA-2 and GATA-3 during development of the mouse central nervous system. *Dev Biol*. 1999;210(2):305–21.
46. Zhou Y, Yamamoto M, Engel JD. GATA2 is required for the generation of V2 interneurons. *Development*. 2000;127(17):3829–38.
47. Rubel CA, Wu SP, Lin L, Wang T, Lanz RB, Li X, et al. A Gata2-dependent transcription network regulates uterine progesterone responsiveness and endometrial function. *Cell Rep*. 2016;17(5):1414–25.
48. Wu D, Sunkel B, Chen Z, Liu X, Ye Z, Li Q, et al. Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer. *Nucleic Acids Res*. 2014;42(6):3607–22.
49. He B, Lanz RB, Fiskus W, Geng C, Yi P, Hartig SM, et al. GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex. *Proc Natl Acad Sci USA*. 2014;111(51):18261–6.
50. Linton MF, Babaev VR, Huang J, Linton EF, Tao H, Yancey PG. Macrophage apoptosis and efferocytosis in the pathogenesis of atherosclerosis. *Circ J*. 2016;80(11):2259–68.
51. Yin C, Vrieze AM, Rosoga M, Akingbasote J, Pawlak EN, Jacob RA, et al. Efferocytic defects in early atherosclerosis are driven by GATA2 overexpression in macrophages. *Front Immunol*. 2020;11:594136.
52. Rodrigues NP, Janzen V, Forkert R, Dombkowski DM, Boyd AS, Orkin SH, et al. Haploinsufficiency of GATA-2 perturbs adult hematopoietic stem-cell homeostasis. *Blood*. 2005;106(2):477–84.
53. Eich C, Arlt J, Vink CS, Solaimani Kartalaei P, Kaimakis P, Mariani SA, et al. In vivo single cell analysis reveals Gata2 dynamics in cells transitioning to hematopoietic fate. *J Exp Med*. 2018;215(1):233–48.
54. Kaimakis P, de Pater E, Eich C, Solaimani Kartalaei P, Kauts ML, Vink CS, et al. Functional and molecular characterization of mouse Gata2-independent hematopoietic progenitors. *Blood*. 2016;127(11):1426–37.
55. Vink CS, Calero-Nieto FJ, Wang X, Maglito A, Mariani SA, Jawaid W, et al. Iterative single-cell analyses define the transcriptome of the first functional hematopoietic stem cells. *Cell Rep*. 2020;31(6):107627.
56. van Lier YF, de Bree GJ, Jonkers RE, Roelofs J, Ten Berge IJM, Rutten CE, et al. Allogeneic hematopoietic cell transplantation in the management of GATA2 deficiency and pulmonary alveolar proteinosis. *Clin Immunol*. 2020;218:108522.
57. Gomes AM, Kurochkin I, Chang B, Daniel M, Law K, Satija N, et al. Cooperative transcription factor induction mediates hemogenic reprogramming. *Cell Rep*. 2018;25(10):2821–35. e7.
58. Mehta C, Johnson KD, Gao X, Ong I, Katsumura KR, McIver SC, et al. Integrating enhancer mechanisms to establish a hierarchical blood development program. *Blood*. 2017;130(Suppl_1):7.
59. Johnson KD, Conn DJ, Shishkova E, Katsumura KR, Liu P, Shen S, et al. Constructing and deconstructing GATA2-regulated cell fate programs to establish developmental trajectories. *J Exp Med*. 2020;217(11). <https://doi.org/10.1084/jem.20191526>
60. Robert-Moreno A, Espinosa L, de la Pompa JL, Bigas A. RBPjkappa-dependent notch function regulates Gata2 and is essential for the formation of intra-embryonic hematopoietic cells. *Development*. 2005;132(5):1117–26.
61. Guiu J, Shimizu R, D'Altri T, Fraser ST, Hatakeyama J, Bresnick EH, et al. Hes repressors are essential regulators of hematopoietic stem cell development downstream of notch signaling. *J Exp Med*. 2013;210(1):71–84.
62. Gillis WQ, St John J, Bowerman B, Schneider SQ. Whole genome duplications and expansion of the vertebrate GATA transcription factor gene family. *BMC Evol Biol*. 2009;9:207.
63. Zhu C, Smith T, McNulty J, Rayla AL, Lakshmanan A, Siekmann AF, et al. Evaluation and application of modularly assembled zinc-finger nucleases in zebrafish. *Development*. 2011;138(20):4555–64.
64. Traver D, Paw BH, Poss KD, Penberthy WT, Lin S, Zon LI. Transplantation and in vivo imaging of multilineage engraftment in zebrafish bloodless mutants. *Nat Immunol*. 2003;4(12):1238–46.
65. Shin M, Nozaki T, Idrizi F, Isogai S, Ogasawara K, Ishida K, et al. Valves are a conserved feature of the zebrafish lymphatic system. *Dev Cell*. 2019;51(3):374–86. e5.
66. Butko E, Distel M, Pouget C, Weijts B, Kobayashi I, Ng K, et al. Gata2b is a restricted early regulator of hemogenic endothelium in the zebrafish embryo. *Development*. 2015;142(6):1050–61.
67. Dobrzycki T, Mahony CB, Krecsmarik M, Koyunlar C, Rispoli R, Peulen-Zink J, et al. Deletion of a conserved Gata2 enhancer impairs haemogenic endothelium programming and adult zebrafish haematopoiesis. *Commun Biol*. 2020;3(1):71.
68. Gioacchino E, Koyunlar C, Zink J, de Looper H, de Jong M, Dobrzycki T, et al. Essential role for Gata2 in modulating lineage output from hematopoietic stem cells in zebrafish. *Blood Adv*. 2021;5(13):2687–700.
69. Avagyan S, Weber MC, Ma S, Prasad M, Mannherz WP, Yang S, et al. Single-cell ATAC-seq reveals GATA2-dependent priming defect in myeloid and a maturation bottleneck in lymphoid lineages. *Blood Adv*. 2021;5(13):2673–86.
70. Come C, Balhuizen A, Bonnet D, Porse BT. Myelodysplastic syndrome patient-derived xenografts: from no options to many. *Haematologica*. 2020;105(4):864–9.
71. Wunderlich M, Chou FS, Link KA, Mizukawa B, Perry RL, Carroll M, et al. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. *Leukemia*. 2010;24(10):1785–8.
72. Krevvata M, Shan X, Zhou C, Dos Santos C, Habineza Ndikuyeze G, Secreto A, et al. Cytokines increase engraftment of human acute myeloid leukemia cells in immunocompromised mice but not engraftment of human myelodysplastic syndrome cells. *Haematologica*. 2018;103(6):959–71.
73. Muguruma Y, Matsushita H, Yahata T, Yumino S, Tanaka Y, Miyachi H, et al. Establishment of a xenograft model of human myelodysplastic syndromes. *Haematologica*. 2011;96(4):543–51.

74. Reinisch A, Thomas D, Corces MR, Zhang X, Gratzinger D, Hong WJ, et al. A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells. *Nat Med*. 2016;22(7):812–21.
75. Song Y, Rongvaux A, Taylor A, Jiang T, Tebaldi T, Balasubramanian K, et al. A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies. *Nat Commun*. 2019;10(1):366.
76. Dever DP, Bak RO, Reinisch A, Camarena J, Washington G, Nicolas CE, et al. CRISPR/Cas9 beta-globin gene targeting in human hematopoietic stem cells. *Nature*. 2016;539(7629):384–9.
77. Tothova Z, Krill-Burger JM, Popova KD, Landers CC, Sievers QL, Yudovich D, et al. Multiplex CRISPR/Cas9-based genome editing in human hematopoietic stem cells models clonal hematopoiesis and myeloid neoplasia. *Cell Stem Cell*. 2017;21(4):547–55. e8.
78. Ferrari S, Jacob A, Beretta S, Unali G, Albano L, Vavassori V, et al. Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking. *Nat Biotechnol*. 2020;38(11):1298–308.
79. Kotini AG, Chang CJ, Chow A, Yuan H, Ho TC, Wang T, et al. Stage-specific human induced pluripotent stem cells map the progression of myeloid transformation to transplantable leukemia. *Cell Stem Cell*. 2017;20(3):315–28. e7.
80. Kotini AG, Papapetrou EP. Engineering of targeted megabase-scale deletions in human induced pluripotent stem cells. *Exp Hematol*. 2020;87:25–32.
81. Wesely J, Kotini AG, Izzo F, Luo H, Yuan H, Sun J, et al. Acute myeloid leukemia iPSCs reveal a role for RUNX1 in the maintenance of human leukemia stem cells. *Cell Rep*. 2020;31(9):107688.
82. Chao MP, Gentles AJ, Chatterjee S, Lan F, Reinisch A, Corces MR, et al. Human AML-iPSCs reacquire leukemic properties after differentiation and model clonal variation of disease. *Cell Stem Cell*. 2017;20(3):329–44. e7.
83. Castano J, Romero-Moya D, Richaud-Patin Y, Giorgetti A. Generation of two heterozygous GATA2 CRISPR/Cas9-edited iPSC lines, R398W and R396Q, for modeling GATA2 deficiency. *Stem Cell Res*. 2021;55:102445.
84. Wang T, Pine AR, Kotini AG, Yuan H, Zamparo L, Starczynowski DT, et al. Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets. *Cell Stem Cell*. 2021;28(6):1074–89. e7.
85. Collin M, Dickinson R, Bigley V. Haematopoietic and immune defects associated with GATA2 mutation. *Br J Haematol*. 2015;169(2):173–87.
86. Bruzzese A, Leardini D, Masetti R, Strocchio L, Girardi K, Algeri M, et al. GATA2 related conditions and predisposition to pediatric myelodysplastic syndromes. *Cancers (Basel)*. 2020;12(10). <https://doi.org/10.3390/cancers12102962>
87. Godley LA. Inherited predisposition to acute myeloid leukemia. *Semin Hematol*. 2014;51(4):306–21.
88. McReynolds LJ, Calvo KR, Holland SM. Germline GATA2 mutation and bone marrow failure. *Hematol Oncol Clin North Am*. 2018;32(4):713–28.
89. Wlodarski MW, Collin M, Horwitz MS. GATA2 deficiency and related myeloid neoplasms. *Semin Hematol*. 2017;54(2):81–6.
90. Shimizu R, Yamamoto M. Quantitative and qualitative impairments in GATA2 and myeloid neoplasms. *IUBMB Life*. 2020;72(1):142–50.
91. Crispino JD, Horwitz MS. GATA factor mutations in hematologic disease. *Blood*. 2017;129(15):2103–10.
92. Chong CE, Venugopal P, Stokes PH, Lee YK, Brautigan PJ, Yeung DTO, et al. Differential effects on gene transcription and hematopoietic differentiation correlate with GATA2 mutant disease phenotypes. *Leukemia*. 2018;32(1):194–202.
93. Zhang SJ, Ma LY, Huang QH, Li G, Gu BW, Gao XD, et al. Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia. *Proc Natl Acad Sci USA*. 2008;105(6):2076–81.
94. Hou HA, Lin YC, Kuo YY, Chou WC, Lin CC, Liu CY, et al. GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution. *Ann Hematol*. 2015;94(2):211–21.
95. Rutsche CV, Haralambieva E, Lysenko V, Balabanov S, Theocharides APA. A patient with a germline GATA2 mutation and primary myelofibrosis. *Blood Adv*. 2021;5(3):791–5.
96. Bodor C, Renneville A, Smith M, Charazac A, Iqbal S, Etancelin P, et al. Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival. *Haematologica*. 2012;97(6):890–4.
97. Kazenwadel J, Secker GA, Liu YJ, Rosenfeld JA, Wildin RS, Cuellar-Rodriguez J, et al. Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature. *Blood*. 2012;119(5):1283–91.
98. West RR, Hsu AP, Holland SM, Cuellar-Rodriguez J, Hickstein DD. Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation. *Haematologica*. 2014;99(2):276–81.
99. Ding LW, Ikezoe T, Tan KT, Mori M, Mayakonda A, Chien W, et al. Mutational profiling of a MonoMAC syndrome family with GATA2 deficiency. *Leukemia*. 2017;31(1):244–5.
100. Camargo JF, Lobo SA, Hsu AP, Zerbe CS, Wormser GP, Holland SM. MonoMAC syndrome in a patient with a GATA2 mutation: case report and review of the literature. *Clin Infect Dis*. 2013;57(5):697–9.
101. McReynolds LJ, Zhang Y, Yang Y, Tang J, Mule M, Hsu AP, et al. Rapid progression to AML in a patient with germline GATA2 mutation and acquired NRAS Q61K mutation. *Leuk Res Rep*. 2019;12:100176.
102. Katsumura KR, Mehta C, Hewitt KJ, Soukup AA, Fraga de Andrade I, Ranheim EA, et al. Human leukemia mutations corrupt but do not abrogate GATA-2 function. *Proc Natl Acad Sci USA* 2018;115(43):E10109–E18.
103. Wehr C, Grotius K, Casadei S, Bleckmann D, Bode SFN, Frye BC, et al. A novel disease-causing synonymous exonic mutation in GATA2 affecting RNA splicing. *Blood*. 2018;132(11):1211–5.
104. Kozyra EJ, Pastor VB, Lefkopoulou S, Sahoo SS, Busch H, Voss RK, et al. Synonymous GATA2 mutations result in selective loss of mutated RNA and are common in patients with GATA2 deficiency. *Leukemia*. 2020;34(10):2673–87.
105. Fox LC, Tan M, Brown AL, Arts P, Thompson E, Ryland GL, et al. A synonymous GATA2 variant underlying familial myeloid malignancy with striking intrafamilial phenotypic variability. *Br J Haematol*. 2020;190(5):e297–301.
106. Fisher KE, Hsu AP, Williams CL, Sayeed H, Merritt BY, Elghetany MT, et al. Somatic mutations in children with GATA2-associated myelodysplastic syndrome who lack other features of GATA2 deficiency. *Blood Adv*. 2017;1(7):443–8.
107. Bluteau O, Sebert M, Leblanc T, Peffault de Latour R, Quentin S, Lainey E, et al. A landscape of germ line mutations in a cohort of inherited bone marrow failure patients. *Blood* 2018;131(7):717–32.
108. Mutsaers PG, van de Loosdrecht AA, Tawana K, Bodor C, Fitzgibbon J, Menko FH. Highly variable clinical manifestations in a large family with a novel GATA2 mutation. *Leukemia*. 2013;27(11):2247–8.
109. Weinberg OK, Kuo F, Calvo KR. Germline predisposition to hemato-lymphoid neoplasia. *Am J Clin Pathol*. 2019;152(3):258–76.
110. Cavalcante de Andrade Silva M, Katsumura KR, Mehta C, Velloso E, Bresnick EH, Godley LA. Breaking the spatial constraint between neighboring zinc fingers: a new germline mutation in GATA2 deficiency syndrome. *Leukemia*. 2021;35(1):264–8.
111. Sahoo SS, Pastor VB, Goodings C, Voss RK, Kozyra EJ, Szvetnik A, et al. Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes. *Nat Med*. 2021;27(10):1806–17.

112. Marciano BE, Olivier KN, Folio LR, Zerbe CS, Hsu AP, Freeman AF, et al. Pulmonary manifestations of GATA2 deficiency. *Chest*. 2021;160(4):1350–9.
113. Cuellar-Rodriguez J, Gea-Banacloche J, Freeman AF, Hsu AP, Zerbe CS, Calvo KR, et al. Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. *Blood*. 2011;118(13):3715–20.
114. Rastogi N, Abraham RS, Chadha R, Thakkar D, Kohli S, Nivargi S, et al. Successful nonmyeloablative allogeneic stem cell transplant in a child with Emberger syndrome and GATA2 mutation. *J Pediatr Hematol Oncol*. 2018;40(6):e383–e8.
115. Holme H, Hossain U, Kirwan M, Walne A, Vulliamy T, Dokal I. Marked genetic heterogeneity in familial myelodysplasia/acute myeloid leukaemia. *Br J Haematol*. 2012;158(2):242–8.
116. Kazenwadel J, Harvey NL. Lymphatic endothelial progenitor cells: origins and roles in lymphangiogenesis. *Curr Opin Immunol*. 2018;53:81–7.
117. Kurata T, Shigemura T, Muramatsu H, Okuno Y, Nakazawa Y. A case of GATA2-related myelodysplastic syndrome with unbalanced translocation der(1;7)(q10;p10). *Pediatr Blood Cancer*. 2017;64(8). <https://doi.org/10.1002/pbc.26419>
118. Wlodarski MW, Sahoo SS, Niemeyer CM. Monosomy 7 in pediatric myelodysplastic syndromes. *Hematol Oncol Clin North Am*. 2018;32(4):729–43.
119. Hirabayashi J, Strahm B, Urbaniak S, Karow A, Cseh A, van den Heuvel-Eibrink M, et al. Unexpected High Frequency of GATA2 Mutations in Children with Non-Familial MDS and Monosomy 7. *Blood*. 2012;120(21):Abstract 1699.
120. Kozyra EJ, Gohring G, Hickstein DD, Calvo KR, DiNardo CD, Dworzak M, et al. Association of unbalanced translocation der(1;7) with germline GATA2 mutations. *Blood*. 2021;138(23):2441–5.
121. Parta M, Shah NN, Baird K, Rafei H, Calvo KR, Hughes T, et al. Allogeneic hematopoietic stem cell transplantation for GATA2 deficiency using a busulfan-based regimen. *Biol Blood Marrow Transplant*. 2018;24(6):1250–9.
122. Pastor Loyola VB, Hirabayashi J, Pohl S, Kozyra E, Catala A, De Moerloose B, et al. Somatic genetic and epigenetic architecture of myelodysplastic syndromes arising from GATA2 deficiency. *Blood*. 2015;126(23):299.
123. Churpek JE, Pyrtel K, Kanchi KL, Shao J, Koboldt D, Miller CA, et al. Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. *Blood*. 2015;126(22):2484–90.
124. Drazer MW, Kadri S, Sukhanova M, Patil SA, West AH, Feurstein S, et al. Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies. *Blood Adv*. 2018;2(2):146–50.
125. Zhang MY, Keel SB, Walsh T, Lee MK, Gulsuner S, Watts AC, et al. Genomic analysis of bone marrow failure and myelodysplastic syndromes reveals phenotypic and diagnostic complexity. *Haematologica*. 2015;100(1):42–8.
126. Keel SB, Scott A, Sanchez-Bonilla M, Ho PA, Gulsuner S, Pritchard CC, et al. Genetic features of myelodysplastic syndrome and aplastic anemia in pediatric and young adult patients. *Haematologica*. 2016;101(11):1343–50.
127. Wang X, Muramatsu H, Okuno Y, Sakaguchi H, Yoshida K, Kawashima N, et al. GATA2 and secondary mutations in familial myelodysplastic syndromes and pediatric myeloid malignancies. *Haematologica*. 2015;100(10):e398–401.
128. Pastor V, Hirabayashi S, Karow A, Wehrle J, Kozyra EJ, Nienhold R, et al. Mutational landscape in children with myelodysplastic syndromes is distinct from adults: specific somatic drivers and novel germline variants. *Leukemia*. 2017;31(3):759–62.
129. Schwartz JR, Ma J, Lamprecht T, Walsh M, Wang S, Bryant V, et al. The genomic landscape of pediatric myelodysplastic syndromes. *Nat Commun*. 2017;8(1):1557.
130. Kozyra E, Hirabayashi S, Pastor Loyola VB, Przychodzen B, Karow A, Catala A, et al. Clonal mutational landscape of childhood myelodysplastic syndromes. *Blood*. 2015;126:1662.
131. West RR, Calvo KR, Embree LJ, Wang W, Tuschong LM, Bauer TR, et al. ASXL1 and STAG2 are common mutations in GATA2 deficiency patients with bone marrow disease and myelodysplastic syndrome. *Blood Adv*. 2022;6(3):793–807.
132. Pastor Loyola VB, Panda PK, Sahoo SS, Szvetnik EA, Kozyra E, Voss RK, et al. Monosomy 7 as the initial hit followed by sequential acquisition of SETBP1 and ASXL1 driver mutations in childhood myelodysplastic syndromes. *Blood*. 2018;132:105.
133. Stieglitz E, Liu YL, Emanuel PD, Castleberry RP, Cooper TM, Shannon KM, et al. Mutations in GATA2 are rare in juvenile myelomonocytic leukemia. *Blood*. 2014;123(9):1426–7.
134. Trottier AM, Godley LA. Inherited predisposition to haematopoietic malignancies: overcoming barriers and exploring opportunities. *Br J Haematol*. 2021;194(4):663–76.
135. Saettini F, Coliva T, Vendemini F, Moratto D, Savoldi G, Borlenghi E, et al. When to suspect GATA2 deficiency in pediatric patients: from complete blood count to diagnosis. *Pediatr Hematol Oncol*. 2021;38(5):510–4.
136. Grossman J, Cuellar-Rodriguez J, Gea-Banacloche J, Zerbe C, Calvo K, Hughes T, et al. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. *Biol Blood Marrow Transplant*. 2014;20(12):1940–8.
137. Bogaert DJ, Laureys G, Naesens L, Mazure D, De Bruyne M, Hsu AP, et al. GATA2 deficiency and haematopoietic stem cell transplantation: challenges for the clinical practitioner. *Br J Haematol*. 2020;188(5):768–73.
138. Simonis A, Fux M, Nair G, Mueller NJ, Haralambieva E, Pabst T, et al. Allogeneic hematopoietic cell transplantation in patients with GATA2 deficiency—a case report and comprehensive review of the literature. *Ann Hematol*. 2018;97(10):1961–73.
139. Wu Z, Gao S, Diamond C, Kajigaya S, Chen J, Shi R, et al. Sequencing of RNA in single cells reveals a distinct transcriptome signature of hematopoiesis in GATA2 deficiency. *Blood Adv*. 2020;4(12):2656–70.
140. Hofmann I, Avagyan S, Stetson A, Guo D, Al-Sayegh H, London WB, et al. Comparison of outcomes of myeloablative allogeneic stem cell transplantation for pediatric patients with bone marrow failure, myelodysplastic syndrome and acute myeloid leukemia with and without germline GATA2 mutations. *Biol Blood Marrow Transplant*. 2020;26(6):1124–30.
141. DiNardo CD, Bannon SA, Roubort M, Franklin A, Mork M, Armanios M, et al. Evaluation of patients and families with concern for predispositions to hematologic malignancies within the hereditary hematologic malignancy clinic (HHMC). *Clin Lymphoma Myeloma Leuk*. 2016;16(7):417–28. e2.
142. Galera P, Hsu AP, Wang W, Droll S, Chen R, Schwartz JR, et al. Donor-derived MDS/AML in families with germline GATA2 mutation. *Blood*. 2018;132(18):1994–8.
143. Catto LFB, Borges G, Pinto AL, Cle DV, Chahud F, Santana BA, et al. Somatic genetic rescue in hematopoietic cells in GATA2 deficiency. *Blood*. 2020;136(8):1002–5.
144. Lattanzi A, Camarena J, Lahiri P, Segal H, Srifa W, Vakulskas CA, et al. Development of beta-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. *Sci Transl Med*. 2021;13(598). <https://doi.org/10.1126/scitranslmed.abf2444>
145. Charlesworth CT, Camarena J, Cromer MK, Vaidyanathan S, Bak RO, Carte JM, et al. Priming human repopulating hematopoietic stem and progenitor cells for Cas9/gRNA gene targeting. *Mol Ther Nucleic Acids*. 2018;12:89–104.
146. Fananas-Baquero S, Quintana-Bustamante O, Dever DP, Alberquilla O, Sanchez-Dominguez R, Camarena J, et al. Clinically relevant gene editing in hematopoietic stem cells for the treatment of pyruvate kinase deficiency. *Mol Ther Methods Clin Dev*. 2021;22:237–48.
147. Cromer MK, Camarena J, Martin RM, Lesch BJ, Vakulskas CA, Bode NM, et al. Gene replacement of alpha-globin with beta-globin

- restores hemoglobin balance in beta-thalassemia-derived hematopoietic stem and progenitor cells. *Nat Med*. 2021;27(4):677–87.
148. Tsai SQ, Zheng Z, Nguyen NT, Liebers M, Topkar VV, Thapar V, et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. *Nat Biotechnol*. 2015;33(2):187–97.
149. Wienert B, Wyman SK, Richardson CD, Yeh CD, Akcakaya P, Porritt MJ, et al. Unbiased detection of CRISPR off-targets in vivo using DISCOVER-seq. *Science*. 2019;364(6437):286–9.

How to cite this article: Kotmayer L, Romero-Moya D, Marin-Bejar O, Kozyra E, Català A, Bigas A, et al. GATA2 deficiency and MDS/AML: Experimental strategies for disease modelling and future therapeutic prospects. *Br J Haematol*. 2022;199(4):482–495. <https://doi.org/10.1111/bjh.18330>